BBIO - BridgeBio Phase 3 data for ATTR-CM drug published in NEJM
2024-01-11 11:08:51 ET
More on BridgeBio Pharma
- BridgeBio Pharma's Robust Pipeline Could Benefit From A Partner
- BridgeBio Pharma: Taking Some Profits
- BridgeBio submits FDA market application for ATTR-CM drug
- BridgeBio draws Buy rating at Cantor citing 100% upside
- Seeking Alpha’s Quant Rating on BridgeBio Pharma
For further details see:
BridgeBio Phase 3 data for ATTR-CM drug published in NEJM